Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma.
Described is a patient with multiple myeloma who, during long-term treatment with alkylating agents, developed cutaneous Kaposi's sarcoma. Patients with multiple myeloma, unlike those with malignant lymphoma, do not usually develop Kaposi's sarcoma during the natural course of the disease. It is suggested that the immunosuppression resulting from the long-term alkylating agent therapy for multiple myeloma may have prediposed this individual to the development of Kaposi's sarcoma.
D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy*; D009378:Neoplasms, Multiple Primary; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000139:chemically induced* / Q000473:pathology
D000477:Alkylating Agents; D008558:Melphalan; D011241:Prednisone